Compare Blackstone Inc (BX) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Blackstone Inc vs Charles River Laboratories Intl. Inc — how do they compare? Blackstone Inc trades at $146.84 (market cap $117.44B), while Charles River Laboratories Intl. Inc trades at $286.53 (market cap $13.46B). The key difference: Blackstone Inc is far larger — about 8.7× Charles River Laboratories Intl. Inc's market cap, and Blackstone Inc pays a 3.55% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| BX | CRL | |
|---|---|---|
Market Cap | $117.44B | $13.46B |
Sector | Financials | Health |
52-Week High | $188.68 | $282.00 |
52-Week Low | $102.12 | $145.57 |
Dividend Yield | 3.55% | — |
Enterprise Value | — | $16.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Blackstone (BX) trades at $145.65, up 2.81% today, with strong technical momentum showing bullish moving averages and approaching resistance at $147. The company demonstrates robust fundamentals with revenue growth from $10.9B in 2024 to $12.4B in 2025 and net income margin of 25.85%. Recent acquisitions including the Aeroplan stake and HSBC's Australian loan portfolio highlight strategic expansion.
Outlook remains positive with analyst consensus at Buy (63%) and $144 price target, though RSI levels suggest potential overbought conditions. Key risks include private credit market strain and integration challenges from recent acquisitions. Earnings consistency with three consecutive beats supports the bullish case.
Charles River Laboratories (CRL) trades at $286.36, up 3.38% today and near its 52-week high of $277.07. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent Q2 2026 results exceeded expectations with EPS of $3.02 versus $2.77 estimate, driving positive sentiment. However, valuation metrics remain elevated with P/E at 684.85 and negative profitability margins.
While technical indicators and analyst consensus (72% buy ratings) support near-term upside, fundamental concerns persist with negative net income margin (-5.96%) and ROE (-7.7%). The stock faces execution risks in maintaining earnings momentum amid competitive pressures. Current price exceeds consensus target of $277.29, suggesting limited near-term upside potential despite positive business inflection.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Blackstone Inc
Blackstone is one of the world's largest alternative asset managers with $940.8 billion in total asset under management, including $683.8 billion in fee-earning asset under management, at the end of June 2022.
Read more on BX →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
